Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Non Operating Income (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Non Operating Income for 17 consecutive years, with $581000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 42.19% to $581000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.4 million through Dec 2025, down 159.61% year-over-year, with the annual reading at -$2.4 million for FY2025, 159.61% down from the prior year.
  • Non Operating Income hit $581000.0 in Q4 2025 for Integra Lifesciences Holdings, up from -$842000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $5.0 million in Q2 2021 to a low of -$1.9 million in Q2 2025.
  • Historically, Non Operating Income has averaged $1.8 million across 5 years, with a median of $1.7 million in 2022.
  • Biggest five-year swings in Non Operating Income: skyrocketed 1116.49% in 2021 and later plummeted 235.42% in 2025.
  • Year by year, Non Operating Income stood at $4.4 million in 2021, then fell by 10.59% to $4.0 million in 2022, then plummeted by 49.05% to $2.0 million in 2023, then tumbled by 50.07% to $1.0 million in 2024, then tumbled by 42.19% to $581000.0 in 2025.
  • Business Quant data shows Non Operating Income for IART at $581000.0 in Q4 2025, -$842000.0 in Q3 2025, and -$1.9 million in Q2 2025.